Evidence map›Paper›PMID 28199346›Full record

ArticlePloS one2017

Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.

Jacopo Azzollini, Chiara Pesenti, Luca Ferrari, Laura Fontana, Mariarosaria Calvello, Bernard Peissel, Giorgio Portera, Silvia Tabano, Maria Luisa Carcangiu, Paola Riva and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Somatic variants of potential clinical significance in the tumors ofHereditary cancer in clinical practice · 2019
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jacopo AzzolliniMedical Genetics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Chiara PesentiDepartment of Pathophysiology & Transplantation, Università degli Studi di Milano, Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Luca FerrariDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy.
Laura FontanaDepartment of Pathophysiology & Transplantation, Università degli Studi di Milano, Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Mariarosaria CalvelloMedical Genetics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Bernard PeisselMedical Genetics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Giorgio PorteraDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy.
Silvia TabanoDepartment of Pathophysiology & Transplantation, Università degli Studi di Milano, Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Maria Luisa CarcangiuPathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paola RivaDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy.
Monica MiozzoDepartment of Pathophysiology & Transplantation, Università degli Studi di Milano, Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID http://orcid.org/0000-0002-6523-4575
Siranoush ManoukianMedical Genetics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
University of Milan · ITFondazione IRCCS Istituto Nazionale dei Tumori · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In BRCA1/2 families, early-onset breast cancer (BrCa) cases may be also observed among non-carrier relatives. These women are considered phenocopies and raise difficult counselling issues concerning the selection of the index case and the residual risks estimate in negative family members. Few studies investigated the presence of potential genetic susceptibility factors in phenocopies, mainly focussing on BrCa-associated single-nucleotide polymorphisms. We hypothesized that, as for other Mendelian diseases, a revertant somatic mosaicism, resulting from spontaneous correction of a pathogenic mutation, might occur also in BRCA pedigrees. A putative low-level mosaicism in phenocopies, which has never been investigated, might be the causal factor undetected by standard diagnostic testing. We selected 16 non-carriers BrCa-affected from 15 BRCA1/2 families, and investigated the presence of mosaicism through MALDI-TOF mass spectrometry. The analyses were performed on available tumour samples (7 cases), blood leukocytes, buccal mucosa and urine samples (2 cases) or on blood only (7 cases). In one family (n.8), real-time PCR was also performed to analyse the phenocopy and her healthy parents. On the 16 phenocopies we did not detect the family mutations neither in the tumour, expected to display the highest mutation frequency, nor in the other analysed tissues. In family 8, all the genotyping assays did not detect mosaicism in the phenocopy or her healthy parents, supporting the hypothesis of a de novo occurrence of the BRCA2 mutation identified in the proband. These results suggest that somatic mosaicism is not likely to be a common phenomenon in BRCA1/2 families. As our families fulfilled high-risk selection criteria, other genetic factors might be responsible for most of these cases and have a significant impact on risk assessment in BRCA1/2 families. Finally, we found a de novo BRCA2 mutation, suggesting that, although rare, this event should be taken into account in the evaluation of high-risk families.

Indexed as

MosaicismAdultBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsDNAEndodermal Sinus TumorFemaleGenetic TestingGenotypeHumansMiddle AgedPedigreePhenotypePolymorphism, Single NucleotideReal-Time Polymerase Chain ReactionBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanDNA

Identifiers

PMID28199346
PMCPMC5310879
OpenAlexW2588958864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.